• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    908 Devices Reports Second Quarter 2024 Financial Results and Reiterates 2024 Revenue Outlook

    8/6/24 7:00:00 AM ET
    $MASS
    Industrial Machinery/Components
    Industrials
    Get the next $MASS alert in real time by email

    Revenue increases 16% compared to prior year, driven by newly acquired handheld products

    908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter ended June 30, 2024.

    "We delivered solid execution on a multitude of fronts in the quarter, including the acquisition and integration of RedWave Technology into our company. With an expanded handheld portfolio, we are now supporting both our new and existing forensics customers more efficiently," said Kevin J. Knopp, CEO and Co-founder. "We also maintained a strong focus on operational excellence during the quarter and have begun to see early benefits of our increasing scale."

    Recent Highlights

    • Revenue of $14.0 million for the second quarter 2024, increasing 16% compared to the second quarter 2023
      • Handheld revenue was $11.1 million, increasing 26% year over year
      • Desktop revenue was $2.9 million, decreasing 9% year over year
      • Recurring revenue was $5.3 million, increasing 33% year over year
      • 38% of revenue was recurring revenue, driven by service and REBEL consumables
    • Gross margin increased 490 basis points to 53% for the second quarter 2024, partly due to timing of production but also as a result of scale across the business including higher handheld service revenues
    • Launched a quantification package that enhances our XplorIR handheld gas and vapor analyzer, enabling first responders to now identify and quantify nearly 5,000 airborne chemicals
    • Completed the commercial integration of RedWave Technology
    • Presented 13 posters at the American Society for Mass Spectrometry (ASMS) conference and were collaborators on three oral presentations with researchers from the University of Wisconsin-Madison and the National Institute for Bioprocessing Research and Training (NIBRT)
    • Appointed Michele M. Leonhart, former administrator of the U.S. Drug Enforcement Administration, to our Board of Directors

    Second Quarter 2024 Financial Results

    Revenue was $14.0 million for the three months ended June 30, 2024, a 16% increase over the prior year period. This was primarily driven by an increase in handheld devices revenue offset by a decrease in desktop devices revenue. The installed base grew to 3,067 devices with 143 handheld devices and 10 desktop devices placed during the second quarter 2024. Recurring revenue represented 38% of total revenues in the quarter.

    Gross profit was $7.4 million for the second quarter of 2024, compared to $5.8 million for the corresponding period in the prior year. Gross margin was 53% as compared to 48% for the corresponding prior year period. Adjusted gross profit was $8.1 million for the second quarter of 2024, compared to $6.0 million for the corresponding period in the prior year. Adjusted gross margin was 58% as compared to 50% for the corresponding prior year period.

    Operating expenses were $21.0 million for the second quarter of 2024, compared to $16.7 million for the corresponding prior year period. This increase was driven by $1.9 million in acquisition and integration costs, the inclusion of two months of operating expenses related to our RedWave acquisition, and stock-based compensation.

    Net loss was $12.5 million for the second quarter of 2024, compared to $9.3 million for the corresponding prior year period. Adjusted EBITDA was a loss of $7.3 million for the second quarter of 2024, compared to a loss of $7.7 million for the second quarter of 2023.

    Cash, cash equivalents and marketable securities were $77.4 million as of June 30, 2024 with no debt outstanding.

    2024 Guidance

    908 Devices continues to expect full year reported 2024 revenue to be in the range of $63.0 million to $65.0 million, representing 25% to 29% growth over full year 2023. This includes $11 million of expected revenue from RedWave Technology, representing 8 months of ownership.

    Webcast Information

    908 Devices will host a conference call to discuss the second quarter 2024 financial results before market open on Tuesday, August 6, 2024 at 5:30 am Pacific Time / 8:30 am Eastern Time. A webcast of the conference call can be accessed at https://ir.908devices.com/news-events/events. The webcast will be archived and available for replay for at least 90 days after the event.

    About 908 Devices

    908 Devices is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing life-altering applications. The Company's devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in forensics, bioprocessing, pharma / biopharma, life sciences research and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of complementary analytical technologies, microfluidic sampling and separations, software automation, and machine learning.

    Non-GAAP Measures of Financial Performance

    To supplement the Company's financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release and presented with detailed reconciliations to comparable GAAP financial results in the tables below:

    • Adjusted Gross Profit is defined as gross profit excluding intangible amortization, acquisition and integration costs, restructuring charges (including the costs of severance), and non-cash expenses related to stock-based compensation.
    • Adjusted Gross Margin is defined as Adjusted Gross Profit expressed as a percentage of total revenue.
    • Adjusted EBITDA is defined as net loss excluding other income, benefit for income taxes, depreciation, intangible amortization, acquisition and integration costs, restructuring charges (including the costs of severance), non-cash expenses related to stock-based compensation, and costs associated with contingent consideration related to the Company's acquisitions and for which the conditions for payment have not yet been achieved.

    The Company's non-GAAP financial results presented in this earnings release exclude certain costs that management believes do not have a direct correlation to future business operations, nor do the resulting charges recorded accurately reflect the performance of ongoing operations for the period in which such charges are recorded, nor do the resulting charges recorded accurately reflect the anticipated cash flows of ongoing operations, and as such, excluding these costs allows management to understand and evaluate core operating performance and trends. However, as there are no standardized methods of calculating these non-GAAP financial measures, the Company's methods may differ from those used by other companies in its industry, and accordingly, the use of these measures may not be directly comparable to similar measures used by others, thus limiting their usefulness for purposes of comparison. Furthermore, these non-GAAP measures have certain limitations since they do not include the impact of certain expenses and cash flows that are reflected in the Company's GAAP financial results. Accordingly, when analyzing the Company's operating performance and guidance, investors should not consider non-GAAP measures in isolation or as a substitute for, or superior to, comparable financial measures prepared in accordance with GAAP. Rather, the Company believes that these non-GAAP financial measures, when viewed in addition to and not in lieu of reported GAAP financial results, provide investors with additional meaningful information to assess financial performance and trends, enable comparison of financial results between periods, and allow for greater transparency with respect to key metrics utilized internally in analyzing and operating the Company's business.

    Forward Looking Statements

    This press release includes "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the Company's future revenue and growth. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management's current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under "Risk Factors" and elsewhere in the Company's filings with the Securities and Exchange Commission which are available on the SEC's website at www.sec.gov. Additional information will be made available in our annual and quarterly reports and other filings that we make from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

    908 DEVICES INC.

    Condensed Consolidated Statements of Operations

    (in thousands, except share and per share amounts)

    (unaudited)

     

     

    Three Months Ended

     

    Six Months Ended

     

     

    June 30,

     

    June 30,

     

     

    2024

     

    2023

     

    2024

     

    2023

    Revenue:

     

     

     

     

     

     

     

     

     

     

     

     

    Product revenue

     

    $

    10,266

     

     

    $

    9,595

     

     

    $

    17,499

     

     

    $

    16,617

     

    Service revenue

     

     

    3,681

     

     

     

    2,354

     

     

     

    6,439

     

     

     

    4,594

     

    Contract revenue

     

     

    100

     

     

     

    145

     

     

     

    100

     

     

     

    370

     

    Total revenue

     

     

    14,047

     

     

     

    12,094

     

     

     

    24,038

     

     

     

    21,581

     

    Cost of revenue:

     

     

     

     

     

     

     

     

     

     

     

     

    Product cost of revenue

     

     

    4,732

     

     

     

    4,800

     

     

     

    7,942

     

     

     

    8,586

     

    Service cost of revenue

     

     

    1,823

     

     

     

    1,448

     

     

     

    3,601

     

     

     

    2,718

     

    Contract cost of revenue

     

     

    74

     

     

     

    52

     

     

     

    74

     

     

     

    99

     

    Total cost of revenue

     

     

    6,629

     

     

     

    6,300

     

     

     

    11,617

     

     

     

    11,403

     

    Gross profit

     

     

    7,418

     

     

     

    5,794

     

     

     

    12,421

     

     

     

    10,178

     

    Operating expenses:

     

     

     

     

     

     

     

     

     

     

     

     

    Research and development

     

     

    6,381

     

     

     

    5,525

     

     

     

    12,171

     

     

     

    10,923

     

    Selling, general and administrative

     

     

    14,597

     

     

     

    11,208

     

     

     

    26,498

     

     

     

    23,211

     

    Total operating expenses

     

     

    20,978

     

     

     

    16,733

     

     

     

    38,669

     

     

     

    34,134

     

    Loss from operations

     

     

    (13,560

    )

     

     

    (10,939

    )

     

     

    (26,248

    )

     

     

    (23,956

    )

    Other income, net

     

     

    943

     

     

     

    1,522

     

     

     

    2,644

     

     

     

    1,955

     

    Loss from operations before income taxes

     

     

    (12,617

    )

     

     

    (9,417

    )

     

     

    (23,604

    )

     

     

    (22,001

    )

    Benefit for income taxes

     

     

    69

     

     

     

    71

     

     

     

    139

     

     

     

    122

     

    Net loss

     

    $

    (12,548

    )

     

    $

    (9,346

    )

     

    $

    (23,465

    )

     

    $

    (21,879

    )

     

     

     

     

     

     

     

     

     

     

     

     

     

    Net loss per share attributable to common stockholders

     

    $

    (0.37

    )

     

    $

    (0.29

    )

     

    $

    (0.70

    )

     

    $

    (0.68

    )

    Weighted average common shares outstanding

     

     

    34,061,933

     

     

     

    32,199,156

     

     

     

    33,386,413

     

     

     

    32,083,122

     

    908 DEVICES INC.

    Condensed Consolidated Balance Sheets

    (in thousands)

    (unaudited)

     

     

    June 30,

     

    December 31,

     

     

    2024

     

    2023

    Assets

     

     

     

     

     

     

    Current assets:

     

     

     

     

     

     

    Cash, cash equivalents and marketable securities

     

    $

    77,383

     

    $

    145,682

    Accounts receivable, net

     

     

    10,987

     

     

    8,989

    Inventory

     

     

    18,589

     

     

    14,938

    Prepaid expenses and other current assets

     

     

    3,485

     

     

    4,181

    Total current assets

     

     

    110,444

     

     

    173,790

    Operating lease, right-of-use assets

     

     

    5,904

     

     

    6,233

    Property and equipment, net

     

     

    3,556

     

     

    3,342

    Goodwill

     

     

    40,220

     

     

    10,367

    Intangible, net

     

     

    47,298

     

     

    7,860

    Other long-term assets

     

     

    1,352

     

     

    1,389

    Total assets

     

    $

    208,774

     

    $

    202,981

    Liabilities and Stockholders' Equity

     

     

     

     

     

     

    Current liabilities:

     

     

     

     

     

     

    Accounts payable and accrued expenses

     

    $

    7,610

     

    $

    9,904

    Deferred revenue

     

     

    11,954

     

     

    10,629

    Operating lease liabilities

     

     

    2,153

     

     

    2,016

    Total current liabilities

     

     

    21,717

     

     

    22,549

    Deferred revenue, net of current portion

     

     

    9,528

     

     

    3,929

    Other long-term liabilities

     

     

    21,170

     

     

    11,012

    Total liabilities

     

     

    52,415

     

     

    37,490

    Total stockholders' equity

     

     

    156,359

     

     

    165,491

    Total liabilities and stockholders' equity

     

    $

    208,774

     

    $

    202,981

    908 DEVICES INC.

    Reconciliations of GAAP to Non-GAAP Financial Measures

    (Unaudited, amounts in thousands, except percentage and per share data)

    In all tables below, totals may not add due to rounding

    Reconciliation from Gross Profit (GAAP) to Adjusted Gross Profit (Non-GAAP) and Margin Percentage:

     

     

    Three Months Ended

     

    Six Months Ended

     

     

    June 30,

     

    June 30,

     

     

    2024

     

    2023

     

    2024

     

    2023

     

     

     

     

     

     

     

     

     

     

     

     

     

    Gross Profit (GAAP)

     

    $

    7,418

     

     

    $

    5,794

     

     

    $

    12,421

     

     

    $

    10,178

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Intangible amortization

     

     

    530

     

     

     

    107

     

     

     

    637

     

     

     

    213

     

    Acquisition and integration costs

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

    Restructuring

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

    Stock-based compensation

     

     

    202

     

     

     

    140

     

     

     

    373

     

     

     

    255

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Adjusted Gross Profit (Non-GAAP)

     

    $

    8,150

     

     

    $

    6,041

     

     

    $

    13,431

     

     

    $

    10,646

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Gross Margin Percentage (GAAP)

     

     

    53

    %

     

     

    48

    %

     

     

    52

    %

     

     

    47

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

    Adjusted Gross Margin Percentage (Non-GAAP)

     

     

    58

    %

     

     

    50

    %

     

     

    56

    %

     

     

    49

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

    Reconciliation from Net Loss (GAAP) to Adjusted EBITDA (Non-GAAP):

     

     

    Three Months Ended

     

    Six Months Ended

     

     

    June 30,

     

    June 30,

     

     

    2024

     

     

    2023

     

     

    2024

     

     

    2023

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Net Loss (GAAP)

     

    $

    (12,548

    )

     

    $

    (9,346

    )

     

    $

    (23,465

    )

     

    $

    (21,879

    )

     

     

     

     

     

     

     

     

     

     

     

     

     

    Adjustments:

     

     

     

     

     

     

     

     

     

     

     

     

    Other income, net

     

     

    (943

    )

     

     

    (1,522

    )

     

     

    (2,644

    )

     

     

    (1,955

    )

    Benefit for income taxes

     

     

    (69

    )

     

     

    (71

    )

     

     

    (139

    )

     

     

    (122

    )

    Depreciation

     

     

    500

     

     

     

    368

     

     

     

    918

     

     

     

    738

     

    Intangible amortization

     

     

    693

     

     

     

    219

     

     

     

    913

     

     

     

    437

     

    Acquisition and integration costs

     

     

    1,950

     

     

     

    -

     

     

     

    1,950

     

     

     

    -

     

    Restructuring

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    524

     

    Stock-based compensation

     

     

    3,096

     

     

     

    2,578

     

     

     

    5,739

     

     

     

    4,744

     

    Contingent consideration

     

     

    -

     

     

     

    65

     

     

     

    -

     

     

     

    230

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Adjusted EBITDA (Non-GAAP)

     

    $

    (7,321

    )

     

    $

    (7,709

    )

     

    $

    (16,728

    )

     

    $

    (17,283

    )

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240806067859/en/

    Get the next $MASS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MASS

    DatePrice TargetRatingAnalyst
    11/13/2024$12.00 → $4.00Outperform → Market Perform
    Leerink Partners
    2/7/2023$14.00Overweight
    Stephens
    3/8/2022$40.00 → $30.00Outperform
    SVB Leerink
    10/15/2021Outperform
    Cowen
    More analyst ratings

    $MASS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 908 Devices Equips rescEU Disaster Preparedness Reserve with Advanced Chemical Detection

      The company's handheld devices are incorporated in strategic CBRN stockpiles 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announced that its devices for rapid chemical detection at the point of need are being included in strategic stockpiles within Europe as part of rescEU, an EU-funded project that is establishing a reserve of disaster response capabilities. These reserves include stockpiles of chemical, biological, radiation and nuclear (CBRN) capabilities for detection, sampling, identification and monitoring due to unintentional disasters or intentional attacks. Over the past six months, the Company has shipped 108 devices to Europ

      4/30/25 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • 908 Devices Receives $2M Order from the Texas Department of Public Safety for Drug Detection and Mitigation

      Multiple handheld MX908 devices will be deployed to detect, identify and mitigate illicit drugs like fentanyl, protecting communities amid the opioid crisis 908 Devices Inc. (NASDAQ:MASS), a pioneer in purpose-built handheld devices for chemical analysis, announces a $2M order from the Texas Department of Public Safety for its MX908 handheld mass spectrometry device. This investment in advanced tools for drug detection builds on an initial order placed last year for several MX908 devices, and is funded through the Community Oriented Policing Services (COPS) grant, a federally funded, state-administered program. The MX908 provides first responders with fast, actionable information when dea

      4/22/25 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • 908 Devices Announces Preliminary First Quarter 2025 Financial Results

      At least 55% reported revenue growth from continuing operations compared to prior year 908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for safety and defense tech applications, today announced preliminary unaudited financial results for the quarter ended March 31, 2025. Preliminary unaudited revenue from continuing operations for the first quarter of 2025 is expected to be at least $11.5 million, compared to $7.4 million of revenue from continuing operations in the first quarter of 2024, reflecting reported growth of approximately 55%. First quarter revenues do not include approximately $1.1 million of additional re

      4/15/25 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • 908 Devices downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded 908 Devices from Outperform to Market Perform and set a new price target of $4.00 from $12.00 previously

      11/13/24 8:05:47 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Stephens initiated coverage on 908 Devices with a new price target

      Stephens initiated coverage of 908 Devices with a rating of Overweight and set a new price target of $14.00

      2/7/23 6:37:28 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • SVB Leerink reiterated coverage on 908 Devices with a new price target

      SVB Leerink reiterated coverage of 908 Devices with a rating of Outperform and set a new price target of $30.00 from $40.00 previously

      3/8/22 4:31:59 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Awm Investment Company, Inc. claimed ownership of 5,199,924 shares (SEC Form 3)

      3 - 908 Devices Inc. (0001555279) (Issuer)

      3/14/25 4:27:06 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • SEC Form 4 filed by President and CEO Knopp Kevin J.

      4 - 908 Devices Inc. (0001555279) (Issuer)

      3/5/25 4:43:30 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • SEC Form 4 filed by Chief Financial Officer Griffith Joseph H. Iv

      4 - 908 Devices Inc. (0001555279) (Issuer)

      3/5/25 4:43:08 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by 908 Devices Inc.

      SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

      11/14/24 5:11:18 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Amendment: SEC Form SC 13G/A filed by 908 Devices Inc.

      SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

      11/14/24 4:25:10 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Amendment: SEC Form SC 13G/A filed by 908 Devices Inc.

      SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

      7/8/24 4:32:41 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    SEC Filings

    See more
    • SEC Form DEFA14A filed by 908 Devices Inc.

      DEFA14A - 908 Devices Inc. (0001555279) (Filer)

      4/28/25 9:03:24 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • SEC Form DEF 14A filed by 908 Devices Inc.

      DEF 14A - 908 Devices Inc. (0001555279) (Filer)

      4/28/25 9:00:24 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • SEC Form SCHEDULE 13G filed by 908 Devices Inc.

      SCHEDULE 13G - 908 Devices Inc. (0001555279) (Subject)

      4/7/25 4:18:42 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    Leadership Updates

    Live Leadership Updates

    See more
    • 908 Devices Appoints Michele M. Leonhart, Former Administrator of the United States Drug Enforcement Administration (DEA), to Its Board of Directors

      908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, has appointed Michele M. Leonhart, the former Administrator of the United States Drug Enforcement Administration (DEA), to serve on its Board of Directors effective immediately. Ms. Leonhart brings a deep understanding of our customers in law enforcement and adjacent markets. Her 34-year career in the DEA encompassed various positions with increasing levels of responsibility, including Special Agent in Charge of the Los Angeles Field Division from 1998 to 2003, Deputy Administrator (nominated by President Bush) from 2003 to 2007, Acting Administrator from 2007 to 2010, and Admini

      6/25/24 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • 908 Devices Appoints Tony J. Hunt, President and CEO, Repligen, to its Board of Directors

      908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spectrometry devices for chemical and biomolecular analysis, has appointed Tony J. Hunt, President and CEO, Repligen Corporation (NASDAQ:RGEN), to serve on its Board of Directors effective immediately. Mr. Hunt brings a deep understanding of the bioprocessing market, with more than 20 years of life sciences management experience. He joined Repligen in 2014 as Chief Operating Officer and was promoted to his current role a year later. Mr. Hunt previously was President of Bioproduction at Life Technologies, which was acquired by Thermo Fisher Scientific in 2014. From 2000 to 2008, he was with Applied Biosystems as

      3/2/22 4:30:00 PM ET
      $MASS
      $RGEN
      Industrial Machinery/Components
      Industrials
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • 908 Devices Expands Scientific Advisory Board, Creates Dedicated Proteomics Panel

      Company appoints six new members to SAB to maximize the company's impact in the proteomics domain 908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the forthcoming appointment of six new individuals to its Scientific Advisory Board (SAB), including Prof. Ileana Cristea, Prof. Jennifer E. Van Eyk, Prof. Anne-Claude Gingras, Prof. Jesper Olsen, Prof. Renã Robinson, and Prof. John Yates. The new SAB members join the board's co-chairs, Christopher D. Brown, CTO 908 Devices; and J. Michael Ramsey, Scientific Founder of 908 Devices and Professor at UNC Chapel Hill, and existing members Prof. Jarrod

      8/2/21 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Knopp Kevin J. bought $64,200 worth of shares (10,000 units at $6.42), increasing direct ownership by 2% to 508,981 units (SEC Form 4)

      4 - 908 Devices Inc. (0001555279) (Issuer)

      5/13/24 4:42:46 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Knopp Kevin J. bought $57,700 worth of shares (10,000 units at $5.77), increasing direct ownership by 2% to 498,981 units (SEC Form 4)

      4 - 908 Devices Inc. (0001555279) (Issuer)

      5/10/24 6:36:05 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Knopp Kevin J. bought $58,300 worth of shares (10,000 units at $5.83), increasing direct ownership by 2% to 488,981 units (SEC Form 4)

      4 - 908 Devices Inc. (0001555279) (Issuer)

      5/9/24 4:34:35 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    Financials

    Live finance-specific insights

    See more
    • 908 Devices Announces Preliminary First Quarter 2025 Financial Results

      At least 55% reported revenue growth from continuing operations compared to prior year 908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for safety and defense tech applications, today announced preliminary unaudited financial results for the quarter ended March 31, 2025. Preliminary unaudited revenue from continuing operations for the first quarter of 2025 is expected to be at least $11.5 million, compared to $7.4 million of revenue from continuing operations in the first quarter of 2024, reflecting reported growth of approximately 55%. First quarter revenues do not include approximately $1.1 million of additional re

      4/15/25 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • 908 Devices Announces Strategic Transformation and Reports Fourth Quarter and Full Year 2024 Financial Results

      Divested desktop portfolio to Repligen for $70 million, including the MAVEN, MAVERICK, REBEL and ZipChip products Fourth quarter 2024 revenue increases 31% and full year 2024 revenue increases 19% compared to prior year Initiates revenue outlook for 2025 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter and full year ended December 31, 2024. Strategic Transformation Realized 908 Devices cements its unique position as a market-leading provider of analytical tools for tackling critical public health and safety crises through the divestiture of its bioprocessing desktop assets to

      3/4/25 7:45:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

      WALTHAM, Mass. and BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc. (NASDAQ:MASS), a pioneer in purpose-built handheld and desktop devices for chemical analysis, announce that Repligen has purchased 908 Devices' desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. 908 Devices remains focused on the growth of its newly expanded handheld device portfolio for vital health and safety applications. The addition of these desktop assets complements and strengthens Repligen's differentiated PAT portfolio that provides its bioph

      3/4/25 7:30:00 AM ET
      $MASS
      $RGEN
      Industrial Machinery/Components
      Industrials
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care